— Know what they know.
Not Investment Advice
Also trades as: AGY.L (LSE) · $vol 0M

AGYTF OTC

Allergy Therapeutics plc
1W: +0.0% 1M: +0.0% 3M: +7.1% YTD: +36.4% 1Y: +76.5% 3Y: -38.3% 5Y: -31.8%
$0.15
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 42 · $756.3M mcap · 332M float · 0.0020% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$756.3M
52W Range0.085-0.15
Volume7,142
Avg Volume6,640
Beta0.83
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOManuel Llobet
Employees612
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2010-02-03
Dominion Way
Worthing, WSX BN14 8SA
GB
44 1903 844 700
About Allergy Therapeutics plc

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms